CoChat

Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease

Open access
Novalic, Zlata, van der Wal, Annemieke M., Leonhard, Wouter N., Koehl, Gudrun, Breuning, Martijn H., Geissler, Edward K., de Heer, Emile, Peters, Dorien J.M. · 2012 · Journal of the American Society of Nephrology
Cited by 93

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Inhibition of the mammalian target of rapamycin (mTOR) shows beneficial effects in animal models of polycystic kidney disease (PKD); however, two clinical trials in patients with autosomal dominant PKD failed to demonstrate a short-term benefit in either the early or progressive stages of disease. The stage of disease during treatment and the dose of mTOR inhibitors may account for these differing results. Here, we studied the effects of a conventional low dose and a higher dose of sirolimus (blood levels of 3 ng/ml and 30-60 ng/ml, respectively) on mTOR activity and renal cystic disease in two Pkd1-mutant mouse models at different stages of the disease. When initiated at early but not late stages of disease, high-dose treatment strongly reduced mTOR signaling in renal tissues, inhibited cystogenesis, accelerated cyst regression, and abrogated fibrosis and the infiltration of immune cells. In contrast, low-dose treatment did not significantly reduce renal cystic disease. Levels of p-S6Rp(Ser240/244), which marks mTOR activity, varied between kidneys; severity of the renal cystic phenotype correlated with the level of mTOR activity. Taken together, these data suggest that long-term treatment with conventional doses of sirolimus is insufficient to inhibit mTOR activity in renal cystic tissue. Mechanisms to increase bioavailability or to target mTOR inhibitors more specifically to kidneys, alone or in combination with other compounds, may improve the potential for these therapies in PKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2011040340

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 93

Metadata

Authors
Novalic, Z., van der Wal, A. M., Leonhard, W. N., Koehl, G., Breuning, M. H., Geissler, E. K., de Heer, E., & Peters, D. J. M.
Venue
Journal of the American Society of Nephrology
Published
2012-05
Volume
23
Issue
5
Pages
842-853
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2119353448
Cited by
93
References
2
FWCI
6.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2011040340
The paper
Novalic, Z., van der Wal, A. M., Leonhard, W. N., Koehl, G., Breuning, M. H., Geissler, E. K., de Heer, E., & Peters, D. J. M. (2012). Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011040340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.